Armstrong Fleming & Moore Inc Boosts Stake in Johnson & Johnson $JNJ

Key Points

• Armstrong Fleming & Moore Inc increased its stake in Johnson & Johnson by 221.5% in the second quarter, holding 12,588 shares valued at approximately $1.9 million by quarter's end.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing an annual yield of 2.7% and a payout ratio of 55.61%.
• The company's stock has a market capitalization of $459.16 billion, trading around $190.66, with a 52-week high of $192.10 and a low of $140.68.

Armstrong Fleming & Moore Inc lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 221.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,588 shares of the company's stock after buying an additional 8,673 shares during the quarter. Johnson & Johnson makes up 1.0% of Armstrong Fleming & Moore Inc's investment portfolio, making the stock its 16th largest holding. Armstrong Fleming & Moore Inc's holdings in Johnson & Johnson were worth $1,923,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $1,369,188,000. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. grew its stake in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock worth $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth $401,420,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE JNJ opened at $190.66 on Friday. The stock has a market cap of $459.16 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $192.10. The business has a 50-day moving average price of $178.48 and a 200 day moving average price of $163.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Bank of America increased their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. UBS Group set a $198.00 price objective on Johnson & Johnson in a report on Friday, October 3rd. Finally, Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.